Publications

A PDF file of each of these papers can be obtained by sending an e-mail request to Angela.Cenci_Nilsson@med.lu.se 

2012

Iderberg H, Francardo V, Pioli E (2012) Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience Mar 21 (Epub ahead of print)

Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA (2012) Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson’s disease. NeuroImage 61: 228-239 

Mela F, Marti M, Bido S, Cenci MA, Morari M (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.  Neurobiol Dis. 45: 573-82

Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by dopamine replacement therapy and deep-brain stimulation for the treatment of Parkinson´s disease. Prog Neurobiol 96:69-86

2011

Cenci MA, Ohlin KE, Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets 10:670-684.

Cenci MA, Widner H (2011) Poor results for retinal cell transplants in Parkinson disease. Nat Rev Neurol 7:424-425.

Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 42:327-340.

Miguelez C, Aristieta A, Cenci MA, Ugedo L (2011) The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study. PLoS One 6:e24679.

Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA (2011) Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134:2339-2357.

2010 

Fasano S, Bezard E, D´Antoni A, Francardo V, Indrigo M, Qin L, Dovero S, Cerovic M, Cenci MA§, Brambilla R§. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa–induced dyskinesia. Proc Natl Acad Sci USA, 107: 21824-9 (2010)*  § shared senior authorship

Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, Bezard E, Descarries L, Cenci MA (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68:619-628.

Burguillos MA, Hajji N, Englund E, Persson A, Cenci AM, Machado A, Cano J, Joseph B, Venero JL (2010) Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: Evidence in Parkinson's disease patients. Neurobiol Dis, in press

Malmlof T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilstrom B (2010) Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Exp Neurol 225:408-415.

Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P (2010) Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J Neurochem 114:499-511.

Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209-233.

Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39:352-361.

2009 

Cenci MA, Ohlin KE (2009) Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 4:S13-17.

Cenci MA, Ohlin KE, Rylander D (2009) Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat Disord 15 Suppl 3:S59-63.

Lane EL, Brundin P, Cenci MA (2009) Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol Dis 35:42-51.

Lane EL, Vercammen L, Cenci MA, Brundin P (2009) Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp Neurol 219:355-358.

Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2009) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem E-published ahead of print.

Lindgren HS, Ohlin KE, Cenci MA (2009) Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 34:2477-2488.

Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330:227-235.

Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, Bloch B, Cenci MA, Surmeier DJ, Hengerer B, Bezard E (2009) Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 65:518-526.

2008 

Lane EL, Soulet D, Vercammen L, Cenci MA, Brundin P (2008) Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol Dis 32:220-228

Picconi B., Paille V., Ghiglieri V., Bagetta V., Barone I., Lindgren H. S., Bernardi G., Cenci A.M., and Calabresi P., L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiology of Disease, 29: 327-335 (2008)

Cenci M.A. and Lindgren H.S., Advances in understanding L-DOPA-induced dyskinesia. Current Opinion in Neurobiology, 17: 665-671 (2008)

2007 

Cenci M. A., Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends in Neurosciences. 30: 236-243 (2007)

Cenci M.A.,  L-DOPA-induced dyskinesia: cellular mechanisms and approaches to therapy. Parkinsonism and Related Disorders, 13/S3: S263-S267 (2007)

Westin J. E., Vercammen L., Strome E., Konradi C. and Cenci M. A., Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biological Psychiatry, 62: 800-810 (2007)

Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., Quack G. and Cenci M. A., Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia. Journal of Neurochemistry, 102: 1395-1409 (2007)

Stefanova N., Köllensperger M., Cenci, A., Poewe W. and Wenning G.K. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Movement Disorders, 22: 969-973 (2007)

Valastro B., Andersson M., Lindgren H. S. and Cenci M. A., Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB. Neuroscience, 144: 198-207 (2007)

Mela F., Marti M., Dekundy A., Danysz W., Morari M. and Cenci M. A., Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson´s disease . Journal of Neurochemistry, 101: 483-497 (2007)

Lindgren H. S., Rylander D., Ohlin K. E., Lundblad M. and Cenci M. A., The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration. Behavioral Brain Research, 177: 150-159 (2007)

Dekundy A., Lundblad M., Danysz W. and Cenci M. A., Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behavioral Brain Research, 179: 76-89 (2007)

2006 

Westin J. E., Lindgren H. S., Gardi J., Nyengaard J. R., Brundin P., Mohapel P. and Cenci MA. (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. Journal of Neuroscience, 26: 9448-9461.

Cenci, MA., and Lundblad, M. (2006) Pre- versus post-synaptic plasticity in L-DOPA-induced dyskinesia. Journal of Neurochemistry, 99: 381-392.

Brundin P, Cenci MA, Wieloch T (2006) On the move to stimulate cell plasticity in the substantia nigra in Parkinson´s Disease. Exp. Neurology, 201: 1-6.

Cenci MA, Hagell P. (2006) Dyskinesia and neural grafting in Parkinson´s disease. In Restorative Therapies in Parkinson´s Disease (P. Brundin, and W. Olanow, Eds.). pp. 184-224. Kluwer Academic/Plenum Publishers, New York, NY.

Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 69:318-326.

Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96:1718-1727.

Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A, Kirik D. (2006) Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis 21:657-668.

Lane EL, Winkler C, Brundin P, Cenci MA. (2006) The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis. 22: 334-345.

2005 

Cenci MA, Lundblad M. (2005) Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease. In Animal Models of Movement Disorders (M. LeDoux, Ed., pp. 193-208. Elsevier Academic Press, San Diego, CA.

Hagell P, Cenci MA. (2005) Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull 68:4-15.

Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA. (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194:66-75.

2004 

Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, Lundblad M, Cenci MA. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17:219-236.

Lundblad M, Picconi B, Lindgren H, Cenci MA. (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123.

Picconi B, Gardoni F, Centonze D, Mauceri D, Cenci MA, Bernardi G, Calabresi P, Di Luca M. (2004) Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24:5283-5291.

Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK (2004) Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 15:630-639.

2003 

Winkler C, Bentlage C, Cenci MA, Nikkhah G, Bjorklund A (2003) Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model. Neuroscience 118:1063-1077.

Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.

Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.

Andersson M, Westin JE, Cenci MA (2003) Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 17:661-666.

2002 

Cenci MA (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23:105-109.

Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186.

Cenci MA, Whishaw IQ, Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3:574-579.

Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132.

2001 

Andersson M, Konradi C, Cenci MA (2001) cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21:9930-9943.

Westin JE, Andersson M, Lundblad M, Cenci MA (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14:1171-1176.

Johansson PA, Andersson M, Andersson KE, Cenci MA (2001) Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis 8:220-239.

2000 

Cenci MA, Kalen P (2000) Serotonin release from mesencephalic raphe neurons grafted to the 5,7-dihydroxytryptamine-lesioned rat hippocampus: effects of behavioral activation and stress. Exp Neurol 164:351-361.

Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 ( Pt 7):1365-1379.

1999 

Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474.

Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94:515-527.

1998 

Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.

1997 

Cenci MA, Campbell K, Bjorklund A (1997) Glutamic acid decarboxylase gene expression in the dopamine-denervated striatum: effects of intrastriatal fetal nigral transplants or chronic apomorphine treatment. Brain Res Mol Brain Res 48:149-155.

1995 

Nikkhah G, Cunningham MG, Cenci MA, McKay RD, Bjorklund A (1995) Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci 15:3548-3561.

1994 

Kokaia M, Cenci MA, Elmer E, Nilsson OG, Kokaia Z, Bengzon J, Bjorklund A, Lindvall O (1994) Seizure development and noradrenaline release in kindling epilepsy after noradrenergic reinnervation of the subcortically deafferented hippocampus by superior cervical ganglion or fetal locus coeruleus grafts. Exp Neurol 130:351-361.

Cenci MA, Bjorklund A (1994) Transection of corticostriatal afferents abolishes the hyperexpression of Fos and counteracts the development of rotational overcompensation induced by intrastriatal dopamine-rich grafts when challenged with amphetamine. Brain Res 665:167-174.

Cenci MA, Kalen P, Duan WM, Bjorklund A (1994) Transmitter release from transplants of fetal ventral mesencephalon or locus coeruleus in the rat frontal cortex and nucleus accumbens: effects of pharmacological and behaviorally activating stimuli. Brain Res 641:225-248.

1993 

Cenci MA, Campbell K, Bjorklund A (1993) Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 57:275-296.

Cenci MA, Bjorklund A (1993) Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Neurosci 5:1062-1070.

Cenci MA, Nilsson OG, Kalen P, Bjorklund A (1993) Characterization of in vivo noradrenaline release from superior cervical ganglia or fetal locus coeruleus transplanted to the subcortically deafferented hippocampus in the rat. Exp Neurol 122:73-87.

1992 

Mandel RJ, Wictorin K, Cenci MA, Bjorklund A (1992) Fos expression in intrastriatal striatal grafts: regulation by host dopaminergic afferents. Brain Res 583:207-215.

Cenci MA, Kalen P, Mandel RJ, Bjorklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res 581:217-228.

Cenci MA, Campbell K, Wictorin K, Bjorklund A (1992) Striatal c-fos Induction by Cocaine or Apomorphine Occurs Preferentially in Output Neurons Projecting to the Substantia Nigra in the Rat. Eur J Neurosci 4:376-380.

Cenci MA, Kalen P, Mandel RJ, Wictorin K, Bjorklund A (1992) Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum. Neuroscience 46:943-957.

1991 

Kalen P, Cenci MA, Lindvall O, Bjorklund A (1991) Host Brain Regulation of Fetal Locus Coeruleus Neurons Grafted to the Hippocampus in 6-Hydroxydopamine-Treated Rats. An Intracerebral Microdialysis Study. Eur J Neurosci 3:905-918.

1990 

Kalen P, Nilsson OG, Cenci MA, Rosengren E, Lindvall O, Bjorklund A (1990) Intracerebral microdialysis as a tool to monitor transmitter release from grafted cholinergic and monoaminergic neurons. J Neurosci Methods 34:107-115.

Kalen P, Cenci MA, Daszuta A, Lindvall O, Bjorklund A (1990) In vivo microdialysis: a new approach for the study of functional activity of grafted monoaminergic neurons and their interaction with the host brain. Prog Brain Res 82:329-338.

Book chapters

Cenci M. A. and Odin P., Dopamine replacement therapy in Parkinson´s Disease: past, present and future. In: Cortico-subcortical dynamics in Parkinson´s disease, ( K.Y. Tseng Ed. - kuei-yuan.tseng@rosalindfranklin.edu), Humana Press and Springer Editorials; in press (2008)

Cenci M. A. and Lundblad M., Ratings of L-DOPA-induced dyskinesia in the unilateral 6-hydroxydopamine lesion model of Parkinson’s disease in rats and mice. In: Current Protocols in Neuroscience (C. Gerfen, A. Holmes, M. Rogawski, D. Sibley, P. Skolnick and S. Wray, Eds), John Wiley & Sons, Inc.; pp. 9.25.1-9.25.23 (2007)

Cenci M. A., Mechanisms of L-DOPA-induced dyskinesia in Parkinson´s disease: What do animal models tell us? In: Recent Breakthroughs in Basal Ganglia Research (E. Bezard, Ed.), Nova Publishing Company; Carbondale IL; pp. 351-360 (2007)

Cenci M. A., and Hagell P., Dyskinesia and neural grafting in Parkinson´s disease. In: Restorative Therapies in Parkinson´s Disease (P. Brundin and W. Olanow, Eds.), Kluwer Academic/Plenum Publishers; New York, NY; pp. 184-224 (2006)

Cenci M. A., and Lundblad M., Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease. In: Animal Models of Movement Disorders (M. LeDoux, Ed.), Elsevier Academic Press; San Diego, CA. ; pp. 193-208 (2005)